Unlocking the potential of EphA2 with precision-guided cancer therapy - bicycle drug conjugates

Sep 23, 2026

Therapeutic advances have improved cancer outcomes, yet patients who cannot tolerate or do not respond to current treatments still require novel options. EphA2 is highly expressed across many solid tumors and is linked to poor prognosis, particularly in cancers that are difficult to treat. This review summarizes EphA2 as an oncology target and traces historical and current clinical development, emphasizing BT5528, a bicycle drug conjugate delivering MMAE with precision-guided tumor distribution and a differentiated safety profile.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

EphA2: a high-value target in oncology

Main body

EphA2-targeting agents and development history

BT5528 composition and mechanism

Conclusion

Keywords

Bennett et al. Journal of Translational Medicine (2026) 24:322 [https://doi.org/10.1186/s12967-026-07870-3](https://doi.org/10.1186/s12967-026-07870-3) Journal of Translational Medicine REVIEW Open Access Unlocking the potential of EphA2 with precision-guided cancer therapy: bicycle drug conjugates Gavin Bennett 1*, Jitka Riedl 1 and Gemma Mudd1 Abstract Background Therapeutic advances have improved cancer survival outcomes for an increasing number of patients, but novel approaches are still urgently needed for patients who cannot tolerate, or do not respond to current treatments. Erythropoietin-producing hepatocellular receptor A2 (EphA2) is highly expressed in a variety of solid tumors, which is associated with poor prognosis, especially in tumors considered difficult-to-treat, such as pancreatic and head and neck cancer. Main body EphA2 has emerged as a promising therapeutic target for the treatment of solid tumors; however, efficacy and safety issues have halted clinical development of previous EphA2-targeting agents including MEDI-547, DS-8895a, MM-310, and dasatinib. Despite these setbacks, interest in targeting EphA2 in solid tumors remains, with ongoing development of investigational therapies such as antibodies, antibody drug conjugates, EphA2 antagonists, peptide drug conjugates, bicyclic peptide drug conjugates, and tyrosine kinase inhibitors. Among these, BT5528, a Bicycle® Drug Conjugate (BDC), has shown an emerging differentiated safety profile, in contrast to prior EphA2-targeting agents, and promising antitumor activity in patients with advanced solid tumors. BT5528 comprises an EphA2-targeting bicyclic (Bicycle) peptide, linked to the cytotoxin monomethyl auristatin E (MMAE) via a valinecitrulline cleavable linker. The high specificity of BT5528 to EphA2, combined with its high affinity, enables precisionguided delivery of MMAE, while its peptidic nature results in rapid distribution and retention of MMAE within the tumor, limited systemic exposure, and liver-sparing renal elimination. Conclusion The preclinical and emerging clinical data for BT5528 suggest that novel approaches to targeting EphA2 can achieve efficacy without the safety issues that plagued earlier agents. Here, we review EphA2 as a target and the historical and current clinical development of EphA2-targeting therapeutic agents. Keywords Antibody drug conjugates, Bicycle® drug conjugate, BT5528, EphA2, Investigational therapies, Solid tumors *Correspondence: Gavin Bennett [gavin.bennett@bicycletx.com](gavin.bennett@bicycletx.com) 1BicycleTx Ltd, Portway Building, Granta Park, Cambridge CB21 6GS, UK © The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.) Bennett et al. Journal of Translational Medicine (2026) 24:322 Background Despite significant therapeutic advances that have improved cancer survival outcomes for an increasing number of pa

FAQs

Why is EphA2 considered a promising target for solid tumors?

EphA2 is highly expressed in many solid tumors and is associated with poor prognosis, contributing to oncogenesis and tumor progression. Its biology supports targeting through receptor signaling pathways.

What limitations affected earlier EphA2-targeting therapies?

Previous EphA2-targeting agents encountered efficacy and safety challenges that halted clinical development. These setbacks created an urgent need for improved strategies.

How does BT5528 deliver its cytotoxin to tumors?

BT5528 links an EphA2-targeting bicyclic peptide to MMAE via a valine-citrulline cleavable linker. High EphA2 specificity and affinity enable precision-guided delivery, with rapid tumor distribution and limited systemic exposure.

Sep 23, 2026

Upload by Maya Linwood